MannKind (MNKD) Q4 2025 earnings review
Surging Revenue Masks a Sudden Collapse in Profitability
MannKind's Q4 delivered accelerating top-line growth of 46% YoY to $112 million, entirely driven by the newly acquired cardiometabolic drug Furoscix and sustained Afrezza growth. However, this revenue surge masked a reversing bottom line. GAAP Net Income collapsed from a $7.4 million profit a year ago to a $15.9 million loss, while Non-GAAP Net Income plunged from $23.0 million to just $1.5 million. The culprit: a massive explosion in operating expenses tied to the scPharma acquisition and preparations for Afrezza's pediatric launch. Furthermore, management quietly discontinued a highly-touted Phase 3 pipeline asset (MNKD-101), raising critical questions about capital allocation.
🐂 Bull Case
Furoscix contributed $23.2 million in its first quarter under MannKind, a 91% YoY increase from what scPharma reported independently in 24Q4. The strategic expansion into cardiometabolic markets is already yielding major top-line results.
Afrezza net sales accelerated to 25% YoY growth ($22.9M), driven by strategic commercial focus. With an FDA PDUFA date of May 29, 2026, for the pediatric indication, a massive new market segment is approaching.
🐻 Bear Case
SG&A expenses surged 144% to $58.4 million, eating up over half of total revenue. Even after backing out $6 million in acquisition costs, structural overhead has doubled, wiping out previous operational leverage.
MannKind discontinued the Phase 3 ICoN-1 study for MNKD-101 (inhaled clofazimine). In previous quarters, management aggressively touted this as an undervalued asset addressing a $1B+ NTM market. The sudden termination represents a major sunk cost and strategy shift.
⚖️ Verdict: ⚪
Neutral. The top-line diversification is impressive and Afrezza's growth is solid, but the severe deterioration in operating margins and the abrupt termination of a late-stage clinical asset demand intense scrutiny before buying into the growth narrative.
Key Themes
The Silent Death of MNKD-101 (Inhaled Clofazimine)
A massive red flag in this report is a brief note deep in the R&D expense explanation: the ICoN-1 clinical study for MNKD-101 was discontinued in Q4 2025. Over the last year, management relentlessly promoted this NTM drug as an undervalued pillar of their orphan lung pipeline, projecting $100M per 1,000 patients. The abrupt discontinuation of a Phase 3 trial that was reportedly 'ahead of schedule on enrollment' just a quarter ago is a severe break in the company's narrative and represents millions in wasted R&D capital.
Operating Expense Explosion Crushes Profitability
Total expenses reversed from a stable trajectory, jumping 138% YoY to $119.6M. SG&A alone hit $58.4M (+144% YoY). While $6M of this was one-time scPharma acquisition costs, the vast majority stems from structural additions: a new Furoscix commercial team, higher headcount, and massive promotional spend for the potential 2026 Afrezza pediatric launch. If these costs persist, the company will require significantly higher sustained revenues to return to meaningful profitability.
Furoscix Immediately Reshapes the Revenue Mix
The $133M scPharma acquisition proved instantly accretive to the top line. Furoscix generated $23.2M in its first quarter under MannKind, overtaking Afrezza ($22.9M) as a leading commercial product. Furthermore, the Furoscix ReadyFlow Autoinjector sNDA was accepted with a PDUFA date of July 26, 2026—a crucial technological innovation that management believes will vastly improve administration and lower Cost of Goods Sold (COGS).
Afrezza Momentum Sustained Ahead of Pediatric Catalyst
Afrezza net sales are accelerating, up 25% YoY to $22.9 million. The ADA Standards of Care in Diabetes – 2026 now explicitly recommends evaluating inhaled insulin at every patient visit, moving it into routine conversation. The FDA also accepted the sBLA for pediatric use, with a PDUFA date of May 29, 2026. Management has previously guided that capturing just 10% of the pediatric market could represent a ~$150M annual revenue opportunity.
Tyvaso DPI Royalties Offer High-Margin Stability
Royalties from United Therapeutics for Tyvaso DPI remain a bedrock of stability, accelerating 24% YoY to $33.6M. Combined with $28M in collaboration and services revenue, the UT partnership provided $61.6M in Q4, acting as the primary non-dilutive financial engine funding the company's cardiometabolic commercial build-out.
Manufacturing and Macro Resilience
Management continues to successfully leverage its Danbury, CT manufacturing facility. By handling primary production domestically, the company mitigates severe global supply chain and tariff risks that are currently plaguing the broader biopharma sector.
Other KPIs
Decelerating/Declining. The cash pile dropped from $286.3 million at the end of Q3 2025, heavily depleted by the $133 million upfront cash used to acquire scPharmaceuticals, combined with the Q4 operational cash burn. The company also took on a massive $318.4 million long-term term loan to facilitate the acquisition, fundamentally altering its leverage profile.
Stable/Managed Decline. Revenues decreased 9% YoY. Management previously communicated that they ceased actively promoting V-Go to focus entirely on Afrezza and Furoscix. This product is being managed for cash flow as it sunsets.
Accelerating dramatically. COGS surged 190% YoY (excluding amortization). While Furoscix generated $23.2M in sales, this steep increase in production and supply chain costs highlights that Furoscix currently carries a significantly lower gross margin profile than MannKind's legacy royalty and endocrine businesses.
Guidance
This target action date represents the most significant commercial catalyst for the company. An approval would unlock a high-need demographic where needle-free administration offers a massive competitive advantage.
The approval of the autoinjector is critical to management's strategy. It aims to deliver an IV-equivalent dose in under 10 seconds, which is expected to drastically improve patient adherence and substantially lower the Cost of Goods Sold compared to the current Furoscix delivery system.
Following the sudden termination of MNKD-101, MNKD-201 is now the sole torchbearer for the company's orphan lung pipeline. A Phase 2 (INFLO-2) trial in IPF is scheduled to enroll its first patient in Q2 2026.
Key Questions
The MNKD-101 Discontinuation
The Phase 3 ICoN-1 study for MNKD-101 was quietly discontinued in Q4 despite earlier claims that enrollment was ahead of schedule for an NTM market you valued at over $1 billion. Was this a clinical failure, a safety signal, or purely a capital allocation decision to fund Furoscix?
Structural Baseline of SG&A
Even after adjusting for $6 million in acquisition-related expenses, SG&A essentially doubled year-over-year. How much of this ~$52 million Q4 adjusted SG&A run-rate is the new structural baseline for 2026, and when do you expect the combined entity to return to GAAP profitability?
Furoscix Gross Margins
Commercial COGS spiked 190% upon consolidating Furoscix. Can you provide the current gross margin profile of Furoscix, and specifically quantify the COGS reduction you expect if the ReadyFlow Autoinjector is approved in July?
Leverage and Cash Flow
You absorbed over $318 million in a new term loan to execute the scPharma acquisition. Given the Q4 operating loss, how are you modeling cash burn over the next 18 months ahead of the anticipated pediatric Afrezza and ReadyFlow launches?